EV Biologics (EV Biologics) Change In Receivables : $-5.85 Mil (TTM As of Dec. 2017)

View and export this data going back to 2015. Start your Free Trial

What is EV Biologics Change In Receivables?

EV Biologics's change in receivables for the quarter that ended in Dec. 2017 was $0.00 Mil. It means EV Biologics's Accounts Receivable stayed the same from Jun. 2017 to Dec. 2017 .

EV Biologics's change in receivables for the fiscal year that ended in Jun. 2017 was $-1.35 Mil. It means EV Biologics's Accounts Receivable increased by $1.35 Mil from Jun. 2016 to Jun. 2017 .

EV Biologics's Accounts Receivable for the quarter that ended in Dec. 2017 was $1.03 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. EV Biologics's Days Sales Outstanding for the three months ended in Dec. 2017 was 2.43.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. EV Biologics's liquidation value for the three months ended in Dec. 2017 was $-7.50 Mil.

EV Biologics Change In Receivables Historical Data

The historical data trend for EV Biologics's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EV Biologics Change In Receivables Chart

EV Biologics Annual Data

Trend

Jun13

Jun14

Jun15

Jun16

Jun17

Change In Receivables

-0.35

-1.08

-4.09

-1.12

-1.35

EV Biologics Quarterly Data
	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Jun17	Dec17
Change In Receivables	Get a 7-Day Free Trial												4.20	-0.11	-5.74	-	-

EV Biologics Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2017 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.85 Mil.

EV Biologics (OTCPK:YECO) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

EV Biologics's Days Sales Outstanding for the quarter that ended in Dec. 2017 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	1.032	/	38.723	*	91
=	2.43

2. In Ben Graham's calculation of liquidation value, EV Biologics's accounts receivable are only considered to be worth 75% of book value:

EV Biologics's liquidation value for the quarter that ended in Dec. 2017 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	8.387	-	16.719	+	0.75 * 1.032	+	0.5 * 0.125
=	-7.50

EV Biologics Change In Receivables Related Terms

Thank you for viewing the detailed overview of EV Biologics's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

EV Biologics (EV Biologics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EV Biologics Inc (OTCPK:YECO) » Definitions » Change In Receivables

Comparable Companies

XCNQ:NIRV ENVB BLCM NLSP BRTX ADTX XKRX:066830 ALLR XMAD:ADL ARTL

Traded in Other Exchanges

N/A

Address

1621 Central Avenue, Cheyenne, WY, USA, 82001

Website

https://www.evbiologics.com

EV Biologics Inc is developing the extraordinary biological properties of extracellular vesicles (EVs) to create the next generation of diagnostic modalities and safe, effective biotherapeutics to improve outcomes of serious clinical conditions, increase natural longevity and transform lives.

Executives

Daniel S Mckinney	director, 10 percent owner, officer: CEO	TWO IFC, 19TH FLOOR, 8 FINANCE STREET, CENTRAL, HONG KONG F4 000000
Michael W Harlan	director	C/O WASTE CONNECTIONS, INC., 610 APPLEWOOD CRESCENT, SUITE 200, VAUGHAN A6 L4K 0C3